Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments

Journal of Clinical Psychiatry

Volumn 59, Issue 6, 1998, Pages 279-288

  Byrne, Sarah E ^a   Rothschild, Anthony J ^b  

^a CAMBRIDGE HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; BROMOCRIPTINE MESILATE; FLUOXETINE; IMIPRAMINE; LITHIUM; MAPROTILINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PEMOLINE; PEMOLINE MAGNESIUM; PHENELZINE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RELAPSE; TREATMENT FAILURE;

EID: 0031903627     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0602     Document Type: Article

References (91)

1. Coryell W, Endicott J, Keller M. Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatry 1990;147: 1627-1633
2. Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(12, suppl):61-69
3. Kupfer DJ. Management of recurrent depression. J Clin Psychiatry 1993; 54(2, suppl):29-33
4. Thase M, Sullivan L. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4(4):261-277
5. Altamura AC, Percudani M. The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. J Clin Psychiatry 1993;54(8, suppl):29-37
6. Goodwin FK. The biology of recurrence: new directions for the pharmacologic bridge. J Clin Psychiatry 1989;50(12, suppl):40-44
7. Keller M, Shapiro R, Lavori P, et al. Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry 1982;39:911-915
8. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52 (5, suppl):28-34
9. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996;57(suppl 2):24-30
10. Robinson D, Lerfald S, Bennet B, et al. Maintenance therapies in recurrent depression: new findings. Psychopharmacol Bull 1991;27:31-39
11. Thase ME. Long-term treatments of recurrent depressive disorders. J Clin Psychiatry 1992;53(9, suppl):32-44
12. Frank E, Prien R, Jarrett D, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851-855
13. Kim H, Delva N, Lawson J. Prophylactic medication for unipolar depressive illness: the place of lithium carbonate in combination with antidepressant medication. Can J Psychiatry 1990;35:107-114
14. Dalery J, Sechter D. Traitement prolonge par antidepresseur. Encephale 1994;20:209-214
15. Montgomery S, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153:69-73
16. Rouillon F, Phillips R, Serrurier D, et al. Recurrence of unipolar depression and efficacy of maprotiline. Encephale 1989;15:527-534
17. Eric L. A prospective, double-blind, comparative, multicentre study of paroxetine and placebo in preventing recurrent major depressive episodes. Biol Psychiatry 1991;29:2545-2555
18. Montgomery S, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
19. Doogan D, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
20. Montgomery S, Rasmussen G. Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1992;6:71-73
21. Bjork K. The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders: a double-blind placebo-controlled study. Acta Psychiatr Scand Suppl 1983;68(suppl 308):182-189
22. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:783-786
23. Coppen A, Ghose K, Montgomery S, et al. Continuation therapy with amitriptyline in depression. Br J Psychiatry 1978;133:28-33
24. Frank E, Kupfer D, Perel J, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
25. Kupfer D, Frank E, Perel J, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
26. Prien R, Mett J, Caffey E. Lithium carbonate and imipramine in prevention of affective episodes. Arch Gen Psychiatry 1973;29:420-425
27. Prien R, Kupfer D, Mansky P, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-1104
28. Cohen B, Baldessarini R. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 1985;142:489-490
29. Donaldson SR. Tolerance to phenelzine and subsequent refractory depression: three cases. J Clin Psychiatry 1989;50:33-35
30. Lieb J, Balter A. Antidepressant tachyphylaxis. Med Hypotheses 1984;15: 279-291
31. Mann J. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 1983;3:363-366
32. Wehr T. Tolerance to antidepressants. Am J Psychiatry 1985;142: 1519-1520
33. Zetin M, Aden G, Moldawdsky R. Tolerance to amoxapine antidepressant effects. Clin Ther 1983;5:638-643
34. Diamond B, Hamner M, Sunde D. Possible tolerance to the antidepressant. anti-obsessive-compulsive, and analgesic effects of fluoxetine [abstract]. Biol Psychiatry 1989;25:155A
35. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995;56:52-55
36. Goldberg JF, Sacks MH, Kocsis JH. Attenuation of response to serotonin reuptake inhibitors [letter]. Am J Psychiatry 1995;152:954
37. Rapport DJ, Calabrese JR. Tolerance to fluoxetine [letter]. J Clin Psychopharmacol 1993;13:361
38. McGrath P, Quitkin F, Klein D. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol 1995;15:289-291
39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
40. Hamilton M. Hamilton psychiatric rating scale for depression. In: Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
41. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv 1997;48:835-837
42. Quitkin F, Stewart J. Loss of drug effects during continuation therapy. Am J Psychiatry 1993;150:562-565
43. Quitkin F, Stewart J, McGrath P, et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993;150: 566-570
44. Rothschild R, Quitkin F. Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosom 1992;58: 170-177
45. Claghorn J, Feighner J. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol 1993;13(suppl 2):23S-27S
46. Dunbar G, Cohn J, Fahre L, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991;159:394-398
47. Feighner J, Cohn J, Fabre L, et al. A study comparing paroxetine, placebo and imipramine in depressed patients. J Affect Disord 1993;28:71-79
48. Janicak P, Davis J. Preskom S, et al. Principles and Practice of Psychopharmacotherapy. 1st ed. Baltimore, Md: Williams & Wilkins; 1993:209-292
49. Cohen B, Harris P, Altesman R, et al. Amoxapine: neuroleptic as well as antidepressant? Am J Psychiatry 1982;139:1165-1167
50. Cohen BM, Baldessarini RJ. Tolerance to antidepressants [letter]. Am J Psychiatry 1985;142:1520
51. Metz A, Shader R. Combination of fluoxetine with pemoline in the treatment of major depressive disorder. Int Clin Psychopharmacol 1991;6: 93-96
52. Kalant H. Drug tolerance and sensitization: a pharmacological overview. In: Goudie A, Emmett-Oglesby M, eds. Psychoactive Drugs: Tolerance and Sensitization. Clifton, NJ: Humana Press; 1989:549-577
53. Lieb J. Antidepressant tachyphylaxis [letter]. J Clin Psychiatry 1990;51:36
54. Chisholm DD. Change in serum antidepressant level at a constant dose of medication [letter]. Am J Psychiatry 1986;143:388
55. Brion S, Orssaud E, Chevalier J, et al. Interaction between cotrimaxazole and antidepressive agents. Encephale 1987;13:123-126
56. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? J Clin Psychiatry 1992;53: 272-277
57. Fichtner C, Jobe T, Braun B. Does fluoxetine have a therapeutic window? Lancet 1991;338:520-521
58. Fichtner CG, Jobe TH, Braun BG. Possible therapeutic window for serotonin reuptake inhibitors [letter with reply]. J Clin Psychiatry 1994;55:36-37
59. Pitchot W, Gonzalez-Moreno A, Ansseau M. Therapeutic window for 5-HT reuptake inhibitors [letter]. Lancet 1992;339:689
60. Altamura A, Montgomery S, Wemicke J. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988;153(suppl3):109-112
61. Pato M, Murphy D, DeVane C. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991;11:224-225
62. Tollefson G. Selective serotonin reuptake inhibitors. In: Schatzberg A, Nemeroff C, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995: 161-182
63. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharm 1993;24:203-220
64. Montgomery S, Baldwin D, Shah A. et al. Plasma-level response relationships with fluoxetine and zimeldine. Clin Neuropharmacol 1990;13(suppl 1):S71-S75
65. Young R, Alexopoulos G, Shindledecker R, et al. Plasma 10-hydroxynortriptyline and therapeutic response in geriatric depression. Neuropsychopharmacology 1988;1:213-215
66. Kraft A. Weight loss and depression. Am J Psychiatry 1991;148:947-948
67. Hurowitz G, Liebowitz M. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol 1993;13:52-56
68. Post RM, Weiss SRB. Sensitization, kindling, and anticonvulsants in mania. J Clin Psychiatry 1989;50(12, suppl):23-30
69. Post R, Rubinow D, Ballenger J. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry 1986;149:191-201
70. Remillard A, Blackshaw S, Danger A. Differential responses to a single antidepressant in recurrent episodes of major depression. Hosp Community Psychiatry 1994;45:359-361
71. Kupfer D, Frank E, Perel J. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 1989;46:771-775
72. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:921-932
73. Theohar C, Fischer-Comelssen K, Akesson H, et al. Bromocriptine as an antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 1981;30:830-842
74. Gupta S, Ghaly N, Dewan M. Augmenting fluoxetine with dextroamphetamine to treat refractory depression. Hosp Community Psychiatry 1992; 43:281-283
75. Linet L. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine. Am J Psychiatry 1989;146:803-804
76. Fawcett J, Kravitz H, Zajecka J, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132
77. Wharton R, Perel J, Dayton P, et al. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971;127:55-61
78. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-76
79. Romero L, Bel N, Casanovas JM, et al. Two actions are better than one: avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors. Int Clin Psychopharmacol 1996;11(suppl 4): 1-8
80. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16:333-338
81. Perez V, Gilaberte I, Fanes D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597
82. Corrigan F. Sodium valproate augmentation of fluoxetine or fluvoxamine effects. Biol Psychiatry 1992;31:1178-1179
83. Kemp L. Sodium valproate as an antidepressant. Br J Psychiatry 1992; 160:121-123
84. Dinan T. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 1993;88:300-301
85. Fava M, Rosenbaum J, McGrath P, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
86. Joffe R, Singer W, Levitt A, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
87. Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988;8:120-124
88. Nemeroff CB. Augmentation regimens for depression. J Clin Psychiatry 1991;52(5, suppl):21-27
89. Seth R, Jennings A, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
90. Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-343
91. Montgomery SA, James D, Montgomery DB. Pharmacological specificity is not the same as clinical selectivity. In: Dahl SG, Gram LF, Paul SM, et al, eds. Clinical Pharmacology in Psychiatry, vol 3. New York, NY: Springer-Verlag; 1987:179-183